Camilla H B Jespersen, Johanna Krøll, Priya Bhardwaj, Carl Johann Hansen, Jesper Svane, Bo G Winkel, Christian Jøns, Peter Karl Jacobsen, Jens Haarbo, Jens Cosedis Nielsen, Jens Brock Johansen, Berit T Philbert, Sam Riahi, Christian Torp-Pedersen, Lars Køber, Jacob Tfelt Hansen, Peter E Weeke
Background Patients with Brugada syndrome (BrS) are recommended to avoid drugs that may increase their risk of arrhythmic events. We examined treatment with such drugs in patients with BrS after their diagnosis. Methods and Results All Danish patients diagnosed with BrS (2006-2018) with >12 months of follow-up were identified from nationwide registries. Nonrecommended BrS drugs were grouped into drugs to "avoid" or "preferably avoid" according to http://www.brugadadrugs.org. Cox proportional hazards analyses were performed to identify factors associated with any nonrecommended BrS drug use, and logistic regression analyses were performed to examine associated risk of appropriate implantable cardioverter defibrillator therapy, mortality, and a combined end point indicating an arrhythmic event of delayed implantable cardioverter defibrillator implantation, appropriate implantable cardioverter defibrillator therapy, and mortality...
March 21, 2023: Journal of the American Heart Association